Baicalein suppresses Coxsackievirus B3 replication by inhibiting caspase-1 and viral protease 2A

Yanyan Dong1, Enze Shao1, Siwei Li1

  • 1Department of Cell Biology, Harbin Medical University, Harbin 150081, China.

Virologica Sinica
|July 18, 2024
PubMed

Insights

Baicalein, a natural compound, effectively combats coxsackievirus B3 (CVB3) infection, reducing viral load and alleviating myocarditis. This flavonoid shows promise as a potential treatment for enterovirus-induced heart inflammation.

Area of Science:

  • Cardiology
  • Virology
  • Pharmacology

Background:

  • Myocarditis, an inflammation of the heart muscle, is a leading cause of dilated cardiomyopathy.
  • Group B coxsackievirus (CVB) is a primary pathogen responsible for viral myocarditis, particularly in young individuals.
  • The absence of vaccines necessitates the development of effective antiviral therapies against CVB.

Purpose of the Study:

  • To investigate the antiviral efficacy of baicalein, a flavonoid derived from Scutellaria baicaleinsis.
  • To determine baicalein's potential as a therapeutic agent for CVB-induced myocarditis.

Main Methods:

  • Assessing the impact of baicalein on CVB3-infected cells, measuring cytopathic effects and cell viability.
  • Quantifying viral protein, RNA, and particle levels following baicalein treatment.
  • Evaluating baicalein's effect on viral replication in the myocardium and myocarditis severity in vivo.
  • Investigating the molecular mechanisms, including inhibition of caspase-1 and viral protease 2A.

Main Results:

  • Baicalein significantly reduced cytopathic effects and enhanced cell viability in CVB3-infected cells.
  • Treatment with baicalein led to substantial decreases in viral protein 3D, viral RNA, and viral particle production.
  • Baicalein demonstrated inhibitory effects in the early stages of CVB3 infection, suppressed myocardial viral replication, and alleviated myocarditis.
  • The antiviral action of baicalein was linked to the inhibition of caspase-1 and viral protease 2A activity.

Conclusions:

  • Baicalein exhibits significant antiviral activity against coxsackievirus B3 (CVB3) infection.
  • Baicalein effectively suppresses viral replication and alleviates CVB3-induced myocarditis.
  • Baicalein represents a potential therapeutic candidate for myocarditis caused by enterovirus infections.

Related Concept Videos

Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...